Viatris Inc., an American pharmaceutical company, has voluntarily recalled one lot of Xanax XR (alprazolam extended-release) 3 mg tablets nationwide after the product failed dissolution specifications — meaning the tablets did not dissolve as required during quality control testing. The recall was initiated in March 2026 and classified by the FDA as Class II on April 8, 2026. No illnesses or adverse events have been reported. The FDA’s Class II designation indicates the probability of serious adverse health consequences is considered remote, but temporary or medically reversible effects are possible.
What’s Being Recalled?
The recall affects a single lot of Xanax XR (alprazolam) extended-release tablets, 3 mg strength, packaged in 60-tablet bottles. The affected lot number is 8177156. The recalled bottles carry an expiration date of February 28, 2027. Only this specific lot is included — other Xanax formulations, strengths, and lot numbers are not affected. The FDA has not indicated how many bottles are included in this lot.
Why Was This Product Recalled?
The recalled Xanax XR tablets failed dissolution specifications during quality control testing. Dissolution testing measures how quickly and completely a tablet breaks down and releases its active ingredient after being taken. When a medication fails dissolution standards, it may not release alprazolam into the bloodstream at the intended rate or concentration. For an extended-release medication like Xanax XR, which is designed to deliver the drug gradually over time, a dissolution failure could mean the medication releases too quickly, too slowly, or inconsistently — potentially affecting how well it controls anxiety or panic disorder symptoms. Alprazolam is a Schedule IV controlled substance and benzodiazepine that requires careful dosing.
What Should You Do?
Check your prescription bottles for Xanax XR 3 mg tablets with lot number 8177156 and an expiration date of February 28, 2027. Do not stop taking your medication without first speaking with your prescribing doctor or pharmacist — abruptly discontinuing a benzodiazepine can cause serious withdrawal symptoms. Contact your pharmacy to arrange a replacement with a non-recalled lot or to discuss alternative options. You can also report any concerns or adverse reactions to the FDA’s MedWatch program at fda.gov/safety/medwatch or by calling 1-800-332-1088.
Source: https://www.fox13news.com/news/xanax-popular-anxiety-medication-recalled-what-know
